Published in BMC Med on April 04, 2013
Strong effects of genetic and lifestyle factors on biomarker variation and use of personalized cutoffs. Nat Commun (2014) 0.97
JAK inhibition using tofacitinib for inflammatory bowel disease treatment: a hub for multiple inflammatory cytokines. Am J Physiol Gastrointest Liver Physiol (2015) 0.93
Restoring the balance: immunotherapeutic combinations for autoimmune disease. Dis Model Mech (2014) 0.92
Coxsackievirus A16 encephalitis during obinutuzumab therapy, Belgium, 2013. Emerg Infect Dis (2014) 0.88
TWEAK/Fn14 Axis-Targeted Therapeutics: Moving Basic Science Discoveries to the Clinic. Front Immunol (2013) 0.88
Immunopathogenesis of ocular Behçet's disease. J Immunol Res (2014) 0.83
Immunotherapeutic strategies in autoimmune uveitis. Autoimmun Rev (2014) 0.80
From historical perspectives to modern therapy: a review of current and future biological treatments for Crohn's disease. Therap Adv Gastroenterol (2015) 0.80
Role of IL-33 and its receptor in T cell-mediated autoimmune diseases. Biomed Res Int (2014) 0.79
Blood gene expression profiling in pediatric systemic lupus erythematosus and systemic juvenile idiopathic arthritis: from bench to bedside. Pediatr Rheumatol Online J (2014) 0.79
Rheumatoid arthritis vaccine therapies: perspectives and lessons from therapeutic ligand epitope antigen presentation system vaccines for models of rheumatoid arthritis. Expert Rev Vaccines (2015) 0.79
Urine metabolome profiling of immune-mediated inflammatory diseases. BMC Med (2016) 0.78
Preferential uptake of antioxidant carbon nanoparticles by T lymphocytes for immunomodulation. Sci Rep (2016) 0.77
Cognate CD4 T-cell licensing of dendritic cells heralds anti-cytomegalovirus CD8 T-cell immunity after human allogeneic umbilical cord blood transplantation. J Virol (2014) 0.77
Activatory and inhibitory Fcγ receptors augment rituximab-mediated internalization of CD20 independent of signaling via the cytoplasmic domain. J Biol Chem (2015) 0.76
Novel pebbles in the mosaic of autoimmunity. BMC Med (2013) 0.76
Anti-Hsp90 therapy in autoimmune and inflammatory diseases: a review of preclinical studies. Cell Stress Chaperones (2016) 0.75
Novel fusion proteins for the antigen-specific staining and elimination of B cell receptor-positive cell populations demonstrated by a tetanus toxoid fragment C (TTC) model antigen. BMC Biotechnol (2016) 0.75
Therapeutic effect of the immunomodulatory drug lenalidomide, but not pomalidomide, in experimental models of rheumatoid arthritis and inflammatory bowel disease. Exp Mol Med (2017) 0.75
Targeting the B-cell pathway in lupus nephritis: current evidence and future perspectives. ScientificWorldJournal (2013) 0.75
Common Adverse Effects of Anti-TNF Agents on Gestation. Obstet Gynecol Int (2016) 0.75
A xenograft model of macrophage activation syndrome amenable to anti-CD33 and anti-IL-6R treatment. JCI Insight (2016) 0.75
Antigen-based immunotherapy for autoimmune disease: current status. Immunotargets Ther (2014) 0.75
B cell-depleting therapy with rituximab or ofatumumab in immunoglobulin A nephropathy or vasculitis with nephritis. Clin Kidney J (2016) 0.75
The relative merits of therapies being developed to tackle inappropriate ('self'-directed) complement activation. Auto Immun Highlights (2016) 0.75
New insights into the pathophysiology of achalasia and implications for future treatment. World J Gastroenterol (2016) 0.75
Biological therapy and dentistry: a review paper. Oral Surg Oral Med Oral Pathol Oral Radiol (2015) 0.75
Identification of human IgG1 variant with enhanced FcRn binding and without increased binding to rheumatoid factor autoantibody. MAbs (2017) 0.75
Peripheral Ulcerative Keratitis Associated with Autoimmune Disease: Pathogenesis and Treatment. J Ophthalmol (2017) 0.75
Impact of healthcare design on patients' perception of a rheumatology outpatient infusion room: an interventional pilot study. Clin Rheumatol (2014) 0.75
Cardiovascular disease in immune-mediated inflammatory diseases: A cross-sectional analysis of 6 cohorts. Medicine (Baltimore) (2017) 0.75
Lubricin binds cartilage proteins, cartilage oligomeric matrix protein, fibronectin and collagen II at the cartilage surface. Sci Rep (2017) 0.75
Characterization of highly concentrated antibody solution - A toolbox for the description of protein long-term solution stability. MAbs (2017) 0.75
Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N Engl J Med (2010) 11.05
Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial. Lancet (2011) 8.89
Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition. N Engl J Med (2005) 6.37
Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial. Arthritis Rheum (2010) 4.57
Treatment of rheumatoid arthritis with the selective costimulation modulator abatacept: twelve-month results of a phase iib, double-blind, randomized, placebo-controlled trial. Arthritis Rheum (2005) 3.64
Efficacy and safety of certolizumab pegol plus methotrexate in active rheumatoid arthritis: the RAPID 2 study. A randomised controlled trial. Ann Rheum Dis (2008) 3.45
Adverse effects of biologics: a network meta-analysis and Cochrane overview. Cochrane Database Syst Rev (2011) 3.44
Golimumab, a human antibody to tumour necrosis factor {alpha} given by monthly subcutaneous injections, in active rheumatoid arthritis despite methotrexate therapy: the GO-FORWARD Study. Ann Rheum Dis (2008) 3.42
A phase II, randomized, double-blind, placebo-controlled, dose-ranging study of belimumab in patients with active systemic lupus erythematosus. Arthritis Rheum (2009) 3.34
Golimumab, a new human tumor necrosis factor alpha antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritis: Twenty-four-week efficacy and safety results of a randomized, placebo-controlled study. Arthritis Rheum (2009) 2.49
Efficacy and safety of golimumab in patients with ankylosing spondylitis: results of a randomized, double-blind, placebo-controlled, phase III trial. Arthritis Rheum (2008) 2.48
Efficacy and safety of certolizumab pegol monotherapy every 4 weeks in patients with rheumatoid arthritis failing previous disease-modifying antirheumatic therapy: the FAST4WARD study. Ann Rheum Dis (2008) 2.35
The efficacy and safety of abatacept in patients with non-life-threatening manifestations of systemic lupus erythematosus: results of a twelve-month, multicenter, exploratory, phase IIb, randomized, double-blind, placebo-controlled trial. Arthritis Rheum (2010) 2.27
Neutralization of interferon-alpha/beta-inducible genes and downstream effect in a phase I trial of an anti-interferon-alpha monoclonal antibody in systemic lupus erythematosus. Arthritis Rheum (2009) 2.14
Long-term safety, efficacy and inhibition of radiographic progression with abatacept treatment in patients with rheumatoid arthritis and an inadequate response to methotrexate: 3-year results from the AIM trial. Ann Rheum Dis (2011) 2.13
Long-term safety and efficacy of tocilizumab, an anti-IL-6 receptor monoclonal antibody, in monotherapy, in patients with rheumatoid arthritis (the STREAM study): evidence of safety and efficacy in a 5-year extension study. Ann Rheum Dis (2008) 2.11
Canakinumab for the treatment of acute flares in difficult-to-treat gouty arthritis: Results of a multicenter, phase II, dose-ranging study. Arthritis Rheum (2010) 2.00
Longterm safety of patients receiving rituximab in rheumatoid arthritis clinical trials. J Rheumatol (2010) 1.91
Ofatumumab, a human anti-CD20 monoclonal antibody, for treatment of rheumatoid arthritis with an inadequate response to one or more disease-modifying antirheumatic drugs: results of a randomized, double-blind, placebo-controlled, phase I/II study. Arthritis Rheum (2010) 1.65
Integrated safety in tocilizumab clinical trials. Arthritis Res Ther (2011) 1.55
Effectiveness and safety of the interleukin 6-receptor antagonist tocilizumab after 4 and 24 weeks in patients with active rheumatoid arthritis: the first phase IIIb real-life study (TAMARA). Ann Rheum Dis (2010) 1.44
Safety of intravenous immunoglobulin (IVIG) therapy. Autoimmun Rev (2006) 1.39
Safety profile and clinical activity of sifalimumab, a fully human anti-interferon α monoclonal antibody, in systemic lupus erythematosus: a phase I, multicentre, double-blind randomised study. Ann Rheum Dis (2011) 1.37
Advances in rheumatology: new targeted therapeutics. Arthritis Res Ther (2011) 1.35
The roles of interleukin-6 in the pathogenesis of rheumatoid arthritis. Arthritis (2011) 1.33
A study of 20 SLE patients with intravenous immunoglobulin--clinical and serologic response. Lupus (1999) 1.31
Ofatumumab, a fully human anti-CD20 monoclonal antibody, in biological-naive, rheumatoid arthritis patients with an inadequate response to methotrexate: a randomised, double-blind, placebo-controlled clinical trial. Ann Rheum Dis (2011) 1.31
Efficacy and safety of retreatment in patients with rheumatoid arthritis with previous inadequate response to tumor necrosis factor inhibitors: results from the SUNRISE trial. J Rheumatol (2010) 1.17
Two-year results from an open-label, multicentre, phase III study evaluating the safety and efficacy of canakinumab in patients with cryopyrin-associated periodic syndrome across different severity phenotypes. Ann Rheum Dis (2011) 1.15
Indirect comparison of tocilizumab and other biologic agents in patients with rheumatoid arthritis and inadequate response to disease-modifying antirheumatic drugs. Semin Arthritis Rheum (2010) 1.15
Drug-induced lupus: an update. Autoimmun Rev (2010) 1.13
Intravenous immunoglobulin and the kidney--a two-edged sword. Semin Arthritis Rheum (2004) 1.11
Tocilizumab, a humanized anti-interleukin-6 receptor antibody, ameliorates joint swelling in established monkey collagen-induced arthritis. Biol Pharm Bull (2008) 0.99
Evidence for the use of intravenous immunoglobulins--a review of the literature. Clin Rev Allergy Immunol (2010) 0.99
Therapy with rituximab for autoimmune pemphigus: results from a single-center observational study on 42 cases with long-term follow-up. J Am Acad Dermatol (2012) 0.97
Targeting CD22 as a strategy for treating systemic autoimmune diseases. Ther Clin Risk Manag (2007) 0.95
Advances in drug therapy for systemic lupus erythematosus. BMC Med (2010) 0.92
Long-term efficacy and safety profile of rilonacept in the treatment of cryopryin-associated periodic syndromes: results of a 72-week open-label extension study. Clin Ther (2012) 0.91
Response of vasculitic peripheral neuropathy to intravenous immunoglobulin. Ann N Y Acad Sci (2005) 0.90
Tocilizumab for the treatment of rheumatoid arthritis and other systemic autoimmune diseases: current perspectives and future directions. Int J Rheumatol (2012) 0.89
Golimumab - a new tool in the armoury against inflammatory arthritis. Ann Med (2011) 0.89
Treatment of systemic lupus erythematosus with epratuzumab. Br J Clin Pharmacol (2011) 0.89
Intravenous immunoglobulin therapy and systemic lupus erythematosus. Clin Rev Allergy Immunol (2005) 0.88
Long-term therapy with intravenous immunoglobulin is beneficial in patients with autoimmune diseases. Clin Rev Allergy Immunol (2012) 0.87
Portuguese guidelines for the use of biological agents in rheumatoid arthritis - October 2011 update. Acta Reumatol Port (2012) 0.87
New insight in the mechanism of action of rituximab: the interferon signature towards personalized medicine. Discov Med (2011) 0.85
Exposure-response relationship of tocilizumab, an anti-IL-6 receptor monoclonal antibody, in a large population of patients with rheumatoid arthritis. J Clin Pharmacol (2013) 0.85
Update on intravenous immunoglobulins (IVIg) mechanisms of action and off- label use in autoimmune diseases. Curr Pharm Des (2011) 0.83
B-cell depletion therapy in systemic sclerosis: experimental rationale and update on clinical evidence. Int J Rheumatol (2011) 0.82
Role of abatacept in the management of rheumatoid arthritis. Clin Ther (2006) 0.81
Low dose intravenous immunoglobulin in systemic lupus erythematosus: analysis of 62 cases. Isr Med Assoc J (2008) 0.81
The steroid-sparing effect of intravenous immunoglobulin in patients with autoimmune diseases. Expert Rev Clin Immunol (2007) 0.78
Safety of rituximab in rheumatoid arthritis: a long-term prospective single-center study of gammaglobulin concentrations and infections. Joint Bone Spine (2012) 0.78
Long-term management of chronic immune thrombocytopenic purpura in adults. Int J Gen Med (2010) 0.77
Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients. Arthritis Rheum (2002) 5.12
International recommendations for the assessment of autoantibodies to cellular antigens referred to as anti-nuclear antibodies. Ann Rheum Dis (2013) 3.99
Human papilloma virus vaccine and primary ovarian failure: another facet of the autoimmune/inflammatory syndrome induced by adjuvants. Am J Reprod Immunol (2013) 3.42
Pathogenesis and natural history of osteonecrosis. Semin Arthritis Rheum (2002) 3.30
Autoantibody explosion in systemic lupus erythematosus: more than 100 different antibodies found in SLE patients. Semin Arthritis Rheum (2004) 3.23
Vitamin D effects on musculoskeletal health, immunity, autoimmunity, cardiovascular disease, cancer, fertility, pregnancy, dementia and mortality-a review of recent evidence. Autoimmun Rev (2013) 2.87
HIV and autoimmunity. Autoimmun Rev (2002) 2.83
Vitamin D and autoimmunity: new aetiological and therapeutic considerations. Ann Rheum Dis (2007) 2.76
Measurement of electrical skin impedance of dermal-visceral zones as a diagnostic tool for inner organ pathologies: a blinded preliminary evaluation of a new technique. Isr Med Assoc J (2005) 2.57
Effects of tobacco smoke on immunity, inflammation and autoimmunity. J Autoimmun (2009) 2.49
Vitamin D and musculoskeletal health, cardiovascular disease, autoimmunity and cancer: Recommendations for clinical practice. Autoimmun Rev (2010) 2.38
Vaccination may be associated with autoimmune diseases. Isr Med Assoc J (2004) 2.14
The Lancet against Israel. Isr Med Assoc J (2013) 2.03
Intensive lipid-lowering therapy: obvious benefits, possible risks. Isr Med Assoc J (2006) 2.02
The role of inflammatory cytokines in the pathogenesis of systemic lupus erythematosus-related atherosclerosis: a novel target for treatment? J Rheumatol (2006) 1.79
Catastrophic antiphospholipid syndrome (CAPS): descriptive analysis of a series of 280 patients from the "CAPS Registry". J Autoimmun (2009) 1.78
Anti-inflammatory and immunosuppressive drugs and reproduction. Arthritis Res Ther (2006) 1.78
Systemic lupus erythematosus in a multiethnic US cohort (LUMINA). XXIII. Baseline predictors of vascular events. Arthritis Rheum (2004) 1.75
Association between vaccination and Guillain-Barré syndrome. Lancet Infect Dis (2013) 1.69
Vitamin D insufficiency in a sunny environment: a demographic and seasonal analysis. Isr Med Assoc J (2010) 1.68
Defining and analyzing geoepidemiology and human autoimmunity. J Autoimmun (2010) 1.67
Matrix metalloproteinase-9 and autoimmune diseases. J Clin Immunol (2006) 1.66
Intravenous immunoglobulin therapy affects T regulatory cells by increasing their suppressive function. J Immunol (2007) 1.64
Assessment of subclinical vascular disease associated with ankylosing spondylitis. J Rheumatol (2011) 1.62
The geoepidemiology of systemic lupus erythematosus. Autoimmun Rev (2009) 1.57
The antiphospholipid syndrome as a neurological disease. Semin Arthritis Rheum (2009) 1.57
The hyperferritinemic syndrome: macrophage activation syndrome, Still's disease, septic shock and catastrophic antiphospholipid syndrome. BMC Med (2013) 1.56
Helicobacter pylori serology in autoimmune diseases - fact or fiction? Clin Chem Lab Med (2013) 1.56
The role of CD40-CD154 interactions in autoimmunity and the benefit of disrupting this pathway. Autoimmunity (2004) 1.54
Gender and autoimmunity. Autoimmun Rev (2006) 1.54
Erdheim-Chester Disease: a comprehensive review of the literature. Orphanet J Rare Dis (2013) 1.54
Hydroxychloroquine: from malaria to autoimmunity. Clin Rev Allergy Immunol (2012) 1.53
Intravenous immunoglobulin: adverse effects and safe administration. Clin Rev Allergy Immunol (2005) 1.52
Inflammatory bowel disease: adverse effect of isotretinoin. Isr Med Assoc J (2009) 1.51
Mechanisms of disease: atherosclerosis in autoimmune diseases. Nat Clin Pract Rheumatol (2006) 1.46
Thymoma and autoimmunity. Cell Mol Immunol (2011) 1.44
Novel aspects of Sjögren's syndrome in 2012. BMC Med (2013) 1.44
Infection and anti-tumor necrosis factor-alpha therapy. Isr Med Assoc J (2003) 1.43
IL-2 receptor alpha deficiency and features of primary biliary cirrhosis. J Autoimmun (2006) 1.43
Intelligent nutrition: health-promoting mechanisms of probiotics. Isr Med Assoc J (2003) 1.42
Systemic thromboembolism in inflammatory bowel disease: mechanisms and clinical applications. Ann N Y Acad Sci (2005) 1.39
Safety of intravenous immunoglobulin (IVIG) therapy. Autoimmun Rev (2006) 1.39
Hippocrates' Oath is challenged. Isr Med Assoc J (2009) 1.38
Infections and SLE. Autoimmunity (2005) 1.38
CD4+CD28- T lymphocytes contribute to early atherosclerotic damage in rheumatoid arthritis patients. Circulation (2004) 1.36
Accelerated atherosclerosis in rheumatoid arthritis. Ann N Y Acad Sci (2007) 1.36
Lupus nephritis: a critical review. Autoimmun Rev (2012) 1.36
Infection, vaccines and other environmental triggers of autoimmunity. Autoimmunity (2005) 1.36
Schizophrenia, autoimmunity and immune system dysregulation: a comprehensive model updated and revisited. J Autoimmun (2006) 1.35
Parotitis as the presenting symptom of Wegener's granulomatosis: case report and meta-analysis. Isr Med Assoc J (2013) 1.35
What is the contents of the magic draft IVIg? Autoimmun Rev (2008) 1.31
Neuropsychiatric syndromes in systemic lupus erythematosus: a meta-analysis. Semin Arthritis Rheum (2010) 1.31
Infections and autoimmunity--friends or foes? Trends Immunol (2009) 1.31
Endothelial dysfunction and atherosclerosis in rheumatoid arthritis: a multiparametric analysis using imaging techniques and laboratory markers of inflammation and autoimmunity. J Rheumatol (2008) 1.29
Pathogenesis of infertility and recurrent pregnancy loss in thyroid autoimmunity. J Autoimmun (2012) 1.28
Vitamin D and autoimmune thyroid diseases. Cell Mol Immunol (2011) 1.28
Autoantibodies involved in neuropsychiatric SLE and antiphospholipid syndrome. Semin Arthritis Rheum (2007) 1.27
The autoimmune bases of infertility and pregnancy loss. J Autoimmun (2012) 1.27
A novel automated indirect immunofluorescence autoantibody evaluation. Clin Rheumatol (2011) 1.27
Novel biomarkers in autoimmune diseases: prolactin, ferritin, vitamin D, and TPA levels in autoimmune diseases. Ann N Y Acad Sci (2007) 1.26
Sjögren's syndrome, the old and the new. Best Pract Res Clin Rheumatol (2012) 1.25
Precocious intima-media thickening in patients with primary Sjögren's syndrome. Arthritis Rheum (2005) 1.25
Practical guidelines for the supplementation of vitamin D and the treatment of deficits in Central Europe - recommended vitamin D intakes in the general population and groups at risk of vitamin D deficiency. Endokrynol Pol (2013) 1.25
Validated methods for assessment of subclinical atherosclerosis in rheumatology. Nat Rev Rheumatol (2012) 1.23
Vitamin D in systemic and organ-specific autoimmune diseases. Clin Rev Allergy Immunol (2013) 1.23
Protective molecules--C-reactive protein (CRP), serum amyloid P (SAP), pentraxin3 (PTX3), mannose-binding lectin (MBL), and apolipoprotein A1 (Apo A1), and their autoantibodies: prevalence and clinical significance in autoimmunity. J Clin Immunol (2005) 1.23
Surviving the butterfly and the wolf: mortality trends in systemic lupus erythematosus. Autoimmun Rev (2004) 1.22
Induction of autoimmune depression in mice by anti-ribosomal P antibodies via the limbic system. Arthritis Rheum (2007) 1.19
Hepatitis B virus (HBV) and autoimmune disease. Clin Rev Allergy Immunol (2008) 1.19
Bacterial induction of autoantibodies to beta2-glycoprotein-I accounts for the infectious etiology of antiphospholipid syndrome. J Clin Invest (2002) 1.19
Autoimmune/inflammatory syndrome induced by adjuvants (ASIA) 2013: Unveiling the pathogenic, clinical and diagnostic aspects. J Autoimmun (2013) 1.19
Juvenile idiopathic arthritis. Autoimmun Rev (2005) 1.18
Are anti-ribosomal P protein antibodies relevant in systemic lupus erythematosus? Clin Rev Allergy Immunol (2007) 1.18
SLE and infections. Clin Rev Allergy Immunol (2003) 1.17
The idiotypic network in autoimmunity: antibodies that bind antibodies that bind antibodies. Nat Med (2004) 1.17
The infectious etiology of vasculitis. Autoimmunity (2009) 1.16
Hyperprolactinemia and autoimmune diseases. Autoimmun Rev (2006) 1.15
Autoantibodies against protective molecules--C1q, C-reactive protein, serum amyloid P, mannose-binding lectin, and apolipoprotein A1: prevalence in systemic lupus erythematosus. Ann N Y Acad Sci (2007) 1.15
The kaleidoscope of autoimmunity: multiple autoimmune syndromes and familial autoimmunity. Expert Rev Clin Immunol (2007) 1.15
Autoimmune/inflammatory syndrome induced by adjuvants (Shoenfeld's syndrome): clinical and immunological spectrum. Expert Rev Clin Immunol (2013) 1.14
Osteonecrosis in patients with SLE. Clin Rev Allergy Immunol (2003) 1.14
Drug-induced lupus: an update. Autoimmun Rev (2010) 1.13
Effects of rituximab treatment on endothelial dysfunction, carotid atherosclerosis, and lipid profile in rheumatoid arthritis. Clin Rheumatol (2009) 1.13
Molecular mimicry and auto-immunity. Clin Rev Allergy Immunol (2007) 1.12
Toll-like receptors and their role in the development of autoimmune diseases. Autoimmunity (2004) 1.12
Oral tolerance with heat shock protein 65 attenuates Mycobacterium tuberculosis-induced and high-fat-diet-driven atherosclerotic lesions. J Am Coll Cardiol (2002) 1.12
Mixed connective tissue disease: an overview of clinical manifestations, diagnosis and treatment. Best Pract Res Clin Rheumatol (2012) 1.12
Harnessing autoimmunity (vitiligo) to treat melanoma: a myth or reality? Ann N Y Acad Sci (2007) 1.11
Post-influenza vaccination vasculitides: a possible new entity. J Clin Rheumatol (2009) 1.11
Tobacco smoking and autoimmune rheumatic diseases. Nat Clin Pract Rheumatol (2007) 1.11
Intravenous immunoglobulin and the kidney--a two-edged sword. Semin Arthritis Rheum (2004) 1.11
Malignancies in autoimmune rheumatic diseases - a mini-review. Gerontology (2010) 1.10
Renal failure and low molecular weight heparins. A dangerous liaison? The case of retroperitoneal hematoma. Isr Med Assoc J (2005) 1.10
Autoimmune bullous diseases the spectrum of infectious agent antibodies and review of the literature. Autoimmun Rev (2011) 1.10
Cognitive impairment in antiphospholipid syndrome: evidence from animal models. Clin Rheumatol (2012) 1.08
Tolerogenic dendritic cells in autoimmune diseases: crucial players in induction and prevention of autoimmunity. Autoimmun Rev (2010) 1.08